 |
|
|
| |
Impact of a 12-Week Oral Regimen of Elbasvir/Grazoprevir (EBR/GZR) On Health-Related Quality of Life (HRQOL) and Fatigue in Treatment-Naïve Patients With Chronic Hepatitis C Virus (HCV) Genotype (GT) 1, 4, or 6 Infection: Data From the C-CORAL Study
|
| |
| |
Reported by Jules Levin
APASL:Asian Pacific Association for the Study of the Liver
Shanghai, China
February 15-19, 2017
Wendy Cheng1; Abhasnee Sobhonslidsuk2; Thuy Thi Thu Pham3; Fu-Sheng Wang4; Youn-Jae Lee5;
Chi -Jen Chu6; Jidong Jia7; Pauline Lindore8; Liwen Liang8; Barvara Evans8;Joy Ginanni8;
Rohit Talwani8; Jean Marie Arduino8
1Royal Perth Hospital, Perth, Australia; 2Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 3Hoa Hao Medical Ltd Company, Hoa Hao Hospital, Ho Chi Minh, Vietnam; 4Beijing 302 Hospital, Beijing, China; 5Inje University Busan Paik Hospital, Busan, South Korea; 6Taipei Veterans General Hospital, Taipei City, Taiwan; 7Beijing Friendship Hospital, Capital Medical University, Beijing, China; 8Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
